Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been assigned a consensus rating of “Buy” from the six analysts that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $19.50.

ZVRA has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Zevra Therapeutics in a report on Wednesday, April 3rd. William Blair reiterated an “outperform” rating on shares of Zevra Therapeutics in a report on Tuesday, March 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a report on Monday, April 1st. Finally, Maxim Group increased their price target on Zevra Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd.

Institutional Trading of Zevra Therapeutics

Several large investors have recently made changes to their positions in ZVRA. VisionPoint Advisory Group LLC acquired a new position in Zevra Therapeutics during the 3rd quarter valued at about $33,000. International Assets Investment Management LLC boosted its stake in Zevra Therapeutics by 555.0% during the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock valued at $43,000 after purchasing an additional 5,550 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Zevra Therapeutics by 134.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock worth $63,000 after buying an additional 5,545 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Zevra Therapeutics during the 1st quarter worth approximately $64,000. Finally, IFG Advisors LLC lifted its position in shares of Zevra Therapeutics by 45.0% during the 1st quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock worth $108,000 after buying an additional 5,800 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Trading Down 2.2 %

Shares of ZVRA stock opened at $4.45 on Thursday. The stock’s fifty day moving average price is $4.72 and its two-hundred day moving average price is $5.43. The company has a market cap of $186.23 million, a PE ratio of -3.30 and a beta of 1.96. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $7.28. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.10 and a current ratio of 2.10.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. Zevra Therapeutics had a negative return on equity of 82.55% and a negative net margin of 181.76%. The company had revenue of $3.43 million during the quarter, compared to analysts’ expectations of $3.52 million. Equities analysts predict that Zevra Therapeutics will post -1.54 EPS for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.